Clinical Trial Results:
A randomized, placebo-controlled, double-blind, multicentre, multiple dose, cohort study with escalating doses to evaluate the safety and efficacy of the humanized monoclonal antibody (mab) BT061 administered subcutaneously or intravenously as 8 repeated doses to patients with moderate to severe chronic plaque psoriasis.
Summary
|
|
EudraCT number |
2008-007458-37 |
Trial protocol |
HU CZ |
Global completion date |
23 May 2011
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
13 Dec 2021
|
First version publication date |
13 Dec 2021
|
Other versions |
|
Summary report(s) |
EudraCT_2008-007458-37_Study Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.